Boji Medical Technology Co., Ltd Class A

Boji Medical Technology Co., Ltd Class A

SSZSE:300404
10.41
CNY
-0.49
(-4.50%)
0.15EPS
97.79P/E
5.68BMarket Cap
Apr 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.57
0.61
0.42
0.29
0.41
0.55
0.71
0.82
0.93
1.15
1.5
1.94
2.26
2.64
Basic EPS, GAAP
0.15
0.16
0.08
0.01
-0.08
0.02
0.02
0.05
0.11
0.08
0.07
0.08
0.08
0.15
Free Cash Flow per Basic Share
0.17
0.01
-0.04
-0.46
-0.11
-0.03
-0.09
0.21
-0.07
-0.24
-0.07
-0.01
0.18
- -
Dividend per Share
- -
0.11
- -
0.03
- -
- -
0.01
0.01
- -
0.02
0.02
0.02
0.02
0.02
Book Value per Share
0.87
0.92
1.37
1.36
1.27
1.3
1.32
1.4
2.22
2.32
2.5
2.55
2.66
2.82
Tangible Book Value per Share
0.84
0.82
1.29
1.28
1.2
1.14
1.15
1.24
2.09
2.18
2.37
2.42
2.52
2.69
Basic Weighted Avg Shares
238
237
302
247
322
315
316
317
349
367
370
382
384
384
Sales/Revenue/Turnover
136
144
127
72
131
172
224
260
324
424
556
742
869
1,016
Operating Margin (%)
30.77
32.06
25.53
0.06
-9.49
12.61
9.45
14.52
16.82
8.2
5.94
5.49
6.91
7.32
Depreciation Expense
3
4
4
5
7
9
14
15
18
21
23
27
28
- -
Net Income, GAAP
35
38
26
2
-24
7
7
17
39
28
24
29
30
58
Effective Tax Rate (%)
15.22
15.09
13.45
- -
- -
26.69
2.35
10.45
7.62
- -
- -
- -
- -
5.99
Profit Margin (%)
25.78
26.39
20.27
2.89
-18.73
4.3
2.94
6.52
11.99
6.53
4.38
3.88
3.51
5.7
Working Capital
141
133
328
237
169
116
117
128
429
401
458
383
435
478
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
5
58
78
41
36
34
Total Equity
206
218
433
430
414
424
449
485
846
889
980
1,002
1,060
1,110
Return on Invested Capital (%)
18.26
17.74
7.49
- -
- -
2.81
2.92
5.28
6.44
- -
- -
- -
- -
5.14
Return on Capital (%)
18.71
17.91
7.13
- -
- -
0.93
0.27
2.13
5.09
- -
- -
- -
- -
5.34
Return on Common Equity (%)
18.71
17.91
7.88
0.48
-5.88
1.81
1.59
3.95
6.18
3.32
2.69
2.98
3.05
5.55

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6
9
9
LT Borrowings
35
34
34
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
386
386
386
Market Capitalization
3,828
3,379
5,682

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,009
1,032
1,049
Cash, Cash Equivalents & STI
394
408
367
Accounts Receivable, Net
206
198
228
Inventories
236
245
252
Total Current Liabilities
524
538
571
Payables & Accruals
- -
- -
- -
ST Debt
6
9
9
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.98%
19.56%
5.77%
Free Cash Flow
-224.31%
-555.48%
-2,755.2%
Net Income, GAAP
-123.65%
22.44%
5.97%
Sales/Revenue/Turnover
25.32%
27.38%
17.06%
Total Cash Common Dividend
- -
79.36%
-21.9%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
167
174
215
186
742
2025
139
223
- -
284
869
2026
220
234
278
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.04
0.03
-0.04
0.08
2025
0.01
0.03
- -
0.02
0.08
2026
0.04
0.05
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
- -
- -
0.02
2025
- -
- -
- -
- -
0.02
2026
- -
0.01
- -
- -
- -

Company Description

CEO
Ting Cun Wang
Full Time Employees
1,256
Sector
Health technology
Industry
Biotechnology
Address
Guangzhou China
IPO Date
Apr 24, 2015
Website
gzboji.com
Business
Boji Medical Technology Co., Ltd. is a comprehensive contract research organization (CRO) and contract development and manufacturing organization (CDMO) that provides full-lifecycle, one-stop outsourcing services for the research, development, and production of pharmaceuticals, biopharmaceuticals, traditional Chinese medicines, and medical devices. The company operates through integrated business segments spanning drug discovery, preclinical testing, clinical trials, regulatory affairs, and commercial manufacturing. Its core service and product offerings include clinical research services, encompassing Phase I to IV clinical trial operations, bioequivalence (BE) studies, site management organization (SMO) services, medical writing, clinical data management, and biostatistical analysis; preclinical research services, comprising target screening, pharmacology, pharmacodynamics, pharmacokinetics, and Good Laboratory Practice (GLP)-compliant toxicology and safety evaluation; pharmaceutical development services, including active pharmaceutical ingredient (API) synthesis, formulation research, analytical method validation, and stability testing; contract development and manufacturing (CDMO/CMO) services, featuring pilot-scale development, chemical synthesis scale-up, finished dosage formulation production, and Marketing Authorization Holder (MAH) incubation; regulatory affairs consulting, delivering China National Medical Products Administration (NMPA) and U.S. Food and Drug Administration (FDA) dual-filing registration support, Investigational New Drug (IND) and New Drug Application (NDA) submissions, and pharmacovigilance; and medical device technical services, covering clinical trial management, performance testing, and product registration. Boji Medical serves multinational pharmaceutical enterprises, domestic drug developers, biotechnology companies, and academic research institutions across China and overseas international markets through subsidiaries such as BioTrialMed and Humphries Pharmaceutical Consulting in the United States. In recent developments, Boji Medical completed a private placement capital raise of approximately RMB 447.73 million to finance upgrades to its Drug Evaluation Center, expand its integrated CDMO/CRO capacities, accelerate proprietary and collaborative traditional Chinese medicine pipelines, and build an intelligent biomedical big data platform. The company also entered into a strategic collaboration with CapitalBio Pharma to advance traditional Chinese medicine R&D through integrated molecular herbal databases, established a strategic alliance with Zhejiang Maiyata Microbial Inspection Intelligent Technology to strengthen clinical operation frameworks and quality control for live biotherapeutic products (LBPs), and formed a joint venture to co-develop GBB101, an innovative long-acting injectable biologic targeted for chronic kidney disease-associated anemia. Founded in 2002, Boji Medical Technology Co., Ltd. is headquartered in Guangzhou, Guangdong Province, China.